Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial - Concepedia

Concepedia

Publication | Open Access

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

DOI Full Paper Access

480

Citations

17

References

2012

Year

S. Gourgou-Bourgade, Caroline Mollévi, Françoise Desseigne, Marc Ychou, Olivier Bouché, Rosine Guimbaud, Y. Bécouarn, Antoine Adenis, Jean‐Luc Raoul, Valérie Boige,

Journal of Clinical Oncology

Abstract

FOLFIRINOX significantly reduces QoL impairment compared with gemcitabine in patients with metastatic pancreatic cancer. Furthermore, baseline QoL scores improved estimation of survival probability when added to baseline clinical and demographic variables.

References

	Year	Citations

Page 1